These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27940664)

  • 1. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children.
    Nakano T; Ishiwada N; Sumitani T; Uemori M; Isobe K;
    Pediatrics; 2016 Dec; 138(6):. PubMed ID: 27940664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
    Kashiwagi S; Watanabe A; Ikematsu H; Awamura S; Okamoto T; Uemori M; Ishida K
    J Infect Chemother; 2013 Aug; 19(4):740-9. PubMed ID: 23732307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
    Kashiwagi S; Watanabe A; Ikematsu H; Uemori M; Awamura S;
    Clin Infect Dis; 2016 Aug; 63(3):330-7. PubMed ID: 27118785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
    Higashiguchi M; Matsumoto T; Fujii T
    Antivir Ther; 2018; 23(2):157-165. PubMed ID: 28869418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
    Watanabe A
    J Infect Chemother; 2013 Feb; 19(1):89-97. PubMed ID: 22907567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
    Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y;
    Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
    Toyama K; Furuie H; Ishizuka H
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population.
    Ambrozaitis A; Gravenstein S; van Essen GA; Rubinstein E; Balciuniene L; Stikleryte A; Crawford C; Elliott M; Shult P
    J Am Med Dir Assoc; 2005; 6(6):367-74. PubMed ID: 16286057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.
    Hayden FG; Gubareva LV; Monto AS; Klein TC; Elliot MJ; Hammond JM; Sharp SJ; Ossi MJ;
    N Engl J Med; 2000 Nov; 343(18):1282-9. PubMed ID: 11058672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
    Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M
    Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    J Infect Chemother; 2013 Apr; 19(2):223-32. PubMed ID: 23085742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2016 Sep; 22(9):605-10. PubMed ID: 27493024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.
    Yoshihara K; Ishizuka H; Kubo Y
    Drug Metab Pharmacokinet; 2013; 28(5):416-26. PubMed ID: 23574886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
    Ishizuka H; Toyama K; Yoshiba S; Okabe H; Furuie H
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3873-8. PubMed ID: 22526307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases.
    Ogawa T; Tanaka K; Ohgino K; Omori N; Betsuyaku T; Sayama K
    J Infect Chemother; 2019 Dec; 25(12):1043-1046. PubMed ID: 31178281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Niwa S; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    Int J Antimicrob Agents; 2012 Nov; 40(5):381-8. PubMed ID: 22871369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.